Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis
The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.
Meningeal Carcinomatosis
DRUG: methotrexate
overall survival, one year
The incidence of adverse reactions, In accordance with the standard of CTCAE, an assessment will be assessed every month, one year|KPS score, In accordance with the standard of KPS(Karnofsky Performance Status,KPS) score, an assessment will be assessed every month, one year
The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in the treatment of meningeal carcinomatosis.